290 related articles for article (PubMed ID: 32386099)
1. Meeting the WHO hepatitis C virus elimination goal: Review of treatment in paediatrics.
Kim NG; Kullar R; Khalil H; Saab S
J Viral Hepat; 2020 Aug; 27(8):762-769. PubMed ID: 32386099
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.
Chiu WN; Hung CH; Lu SN; Chen MY; Tung SY; Wei KL; Lu CK; Chen CH; Hu TH; Hu JH; Chen WM; Chang TS
J Viral Hepat; 2020 Sep; 27(9):866-872. PubMed ID: 32343472
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Glecaprevir/Pibrentasvir and Sofosbuvir/Ledipasvir in Patients with Hepatitis C Virus Genotype 1 and 2 in South Korea.
Shin HD; Song IH; Lee SH; Kim HS; Lee TH; Eun HS; Kim SH; Lee BS; Chae HB; Kim SH; Song MJ; Ko SY; Kim SB
Korean J Gastroenterol; 2024 Mar; 83(3):111-118. PubMed ID: 38522854
[TBL] [Abstract][Full Text] [Related]
4. Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.
Aragri M; Milana M; Di Maio VC; Lenci I; Carioti L; Perno CF; Svicher V; Angelico M; Ceccherini-Silberstein F
Clin Microbiol Infect; 2020 Sep; 26(9):1266-1268. PubMed ID: 32240711
[No Abstract] [Full Text] [Related]
5. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
6. High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Pérez AB; Chueca N; García-Deltoro M; Martínez-Sapiña AM; Lara-Pérez MM; García-Bujalance S; Aldámiz-Echevarría T; Vera-Méndez FJ; Pineda JA; Casado M; Pascasio JM; Salmerón J; Alados-Arboledas JC; Poyato A; Téllez F; Rivero-Juárez A; Merino D; Vivancos-Gallego MJ; Rosales-Zábal JM; García F;
J Hepatol; 2019 Nov; 71(5):876-888. PubMed ID: 31279901
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
Chen JJ; Chiu YC; Lee PL; Tung HD; Chiu HC; Chien SC; Cheng PN
J Formos Med Assoc; 2022 Nov; 121(11):2265-2272. PubMed ID: 35581112
[TBL] [Abstract][Full Text] [Related]
8. Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment.
Liu CH; Yang SS; Peng CY; Lin WT; Liu CJ; Su TH; Tseng TC; Chen PJ; Chen DS; Kao JH
J Viral Hepat; 2020 Jun; 27(6):568-575. PubMed ID: 31981264
[TBL] [Abstract][Full Text] [Related]
9. Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan.
Huang CF; Kuo HT; Chang TS; Lo CC; Hung CH; Huang CW; Chong LW; Cheng PN; Yeh ML; Peng CY; Cheng CY; Huang JF; Bair MJ; Lin CL; Yang CC; Wang SJ; Hsieh TY; Lee TH; Lee PL; Wu WC; Lin CL; Su WW; Yang SS; Wang CC; Hu JT; Mo LR; Chen CT; Huang YH; Chang CC; Huang CS; Chen GY; Kao CN; Tai CM; Liu CJ; Lee MH; Tsai PC; Dai CY; Kao JH; Lin HC; Chuang WL; Chen CY; Tseng KC; Yu ML
Sci Rep; 2021 Dec; 11(1):23473. PubMed ID: 34873250
[TBL] [Abstract][Full Text] [Related]
10. Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.
Nonomura A; Tamori A; Hai H; Kozuka R; Fujii H; Uchida-Kobayashi S; Enomoto M; Kawada N
Intern Med; 2021 Nov; 60(21):3441-3445. PubMed ID: 34024853
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
Margusino-Framiñán L; Cid-Silva P; Rotea-Salvo S; Mena-de-Cea Á; Suárez-López F; Vázquez-Rodríguez P; Delgado-Blanco M; Sanclaudio-Luhia AI; Martín-Herranz I; Castro-Iglesias Á
Eur J Hosp Pharm; 2020 Mar; 27(e1):e41-e47. PubMed ID: 32296504
[TBL] [Abstract][Full Text] [Related]
12. Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.
Lampertico P; Mauss S; Persico M; Barclay ST; Marx S; Lohmann K; Bondin M; Zhang Z; Marra F; Belperio PS; Wedemeyer H; Flamm S
Adv Ther; 2020 Sep; 37(9):4033-4042. PubMed ID: 32754824
[TBL] [Abstract][Full Text] [Related]
13. Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection.
Sise ME; Goldberg DS; Kort JJ; Schaubel DE; Alloway RR; Durand CM; Fontana RJ; Brown RS; Friedewald JJ; Prenner S; Landis JR; Fernando M; Phillips CC; Woodle ES; Rike-Shields A; Sherman KE; Elias N; Williams WW; Gustafson JL; Desai NM; Barnaba B; Norman SP; Doshi M; Sultan ST; Aull MJ; Levitsky J; Belshe DS; Chung RT; Reese PP
J Am Soc Nephrol; 2020 Nov; 31(11):2678-2687. PubMed ID: 32843477
[TBL] [Abstract][Full Text] [Related]
14. Real-World Effectiveness of Direct-Acting Antiviral Regimens against Hepatitis C Virus (HCV) Genotype 3 Infection: A Systematic Review and Meta-Analysis.
Zhuang L; Li J; Zhang Y; Ji S; Li Y; Zhao Y; Li B; Li W; Quan M; Duan Y; Zhao H; Cheng D; Wang X; Ou W; Xing H
Ann Hepatol; 2021; 23():100268. PubMed ID: 33059055
[TBL] [Abstract][Full Text] [Related]
15. [Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure].
Tergast TL; Kordecki N; Ohlendorf V; Beier C; Sandmann L; Wedemeyer H; Cornberg M; Maasoumy B
Z Gastroenterol; 2022 Jun; 60(6):959-962. PubMed ID: 34666403
[TBL] [Abstract][Full Text] [Related]
16. High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence.
Zamor PJ; Brown A; Dylla DE; Dillon JF; Luetkemeyer AF; Feld JJ; Mutimer D; Ghalib R; Crown E; Lovell SS; Hu Y; Moreno C; Nelson DR; Colombo M; Papatheodoridis G; Rockstroh JK; Skoien R; Lawitz E; Jacobson IM
Am J Gastroenterol; 2021 Sep; 116(9):1896-1904. PubMed ID: 34465693
[TBL] [Abstract][Full Text] [Related]
17. Feasibility, safety, efficacy and potential scaling-up of sofosbuvir-based HCV treatment in Central and West Africa: (TAC ANRS 12311 trial).
Lacombe K; Moh R; Chazallon C; Lemoine M; Sylla B; Fadiga F; Le Carrou J; Marcellin F; Kouanfack C; Ciaffi L; Sartre MT; Sida MB; Diallo A; Gozlan J; Seydi M; Cissé V; Danel C; Girard PM; Toni TD; Minga A; Boyer S; Carrieri P; Attia A;
Sci Rep; 2024 May; 14(1):10244. PubMed ID: 38702350
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection.
Zhou HJ; Wu G; Li JM; Naidoo N; Xie YX; Feng BL; Wang P; Luo JW
Ann Palliat Med; 2021 Oct; 10(10):10313-10326. PubMed ID: 34670381
[TBL] [Abstract][Full Text] [Related]
19. High viral load predicts virologic failure in chronic genotype 2 hepatitis C virus-infected patients receiving glecaprevir/pibrentasvir therapy.
Chen WM; Wei KL; Tung SY; Shen CH; Chang TS; Yen CW; Hsieh YY; Chiu WN; Hu JH; Lu SN; Hung CH
J Formos Med Assoc; 2020 Nov; 119(11):1593-1600. PubMed ID: 32839045
[TBL] [Abstract][Full Text] [Related]
20. An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan.
Yu ML; Tai CM; Mo LR; Kuo HT; Huang CF; Tseng KC; Lo CC; Bair MJ; Wang SJ; Huang JF; Yeh ML; Chen CT; Tsai MC; Huang CW; Lee PL; Yang TH; Huang YH; Chong LW; Chen CL; Yang CC; Hung CH; Yang SS; Cheng PN; Hsieh TY; Hu JT; Wu WC; Cheng CY; Chen GY; Zhou GX; Tsai WL; Kao CN; Lin CL; Wang CC; Lin TY; Lin CL; Su WW; Lee TH; Chang TS; Liu CJ; Dai CY; Chen CY; Kao JH; Lin HC; Chuang WL; Peng CY
Hepatol Int; 2024 Apr; 18(2):461-475. PubMed ID: 38246899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
